Oric Pharmaceuticals (ORIC) Accumulated Expenses (2019 - 2026)

Oric Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $14.9 million for Q1 2026.

• Quarterly Accumulated Expenses rose 19.42% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 19.42% YoY) and the FY2025 annual result came in at $8.1 million, up 5.83% from the prior year.
• Accumulated Expenses was $14.9 million for Q1 2026 at Oric Pharmaceuticals, up from $8.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.3 million in Q3 2025 and bottomed at $2.8 million in Q2 2022.
• A 5-year average of $11.4 million and a median of $12.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 552.89% — and 2024, when it slumped 63.8%.
• Oric Pharmaceuticals' Accumulated Expenses stood at $14.1 million in 2022, then slumped by 53.59% to $6.5 million in 2023, then grew by 17.14% to $7.6 million in 2024, then advanced by 5.83% to $8.1 million in 2025, then surged by 83.79% to $14.9 million in 2026.
• Business Quant data shows ORIC's Accumulated Expenses at $14.9 million in Q1 2026, $8.1 million in Q4 2025, and $17.3 million in Q3 2025.